Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Research Question:
How well does the drug, selpercatinib, works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent)?

Basic Study Information

Purpose:
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Location: University of Rochester Medical Center
Study Reference #: CLUN20016

Lead Researcher (Principal Investigator)

Lead Researcher:  Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Return to Search